Shares Outstanding Shares Outstanding n/a Close	61.98M
Shares Change (YoY) Shares Change (YoY) n/a Close	4.66%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	3%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	99.99%
Shares Floating Shares Floating n/a Close	58.35M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	85
FTD / Avg. Volume FTD / Avg. Volume n/a Close	0.01%

Short Selling Information

The latest short interest is 5.21M, so 8.4% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	5.21M
Short % of Shares Out Short % of Shares Out n/a Close	8.4%
Short % of Float Short % of Float n/a Close	10.08%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	7.58

Valuation Ratios

The PE ratio is 8.64 and the forward PE ratio is -302.5. Protagonist Therapeutics's PEG ratio is -0.02.

PE Ratio PE Ratio n/a Close	8.64
Forward PE Forward PE n/a Close	-302.5
PS Ratio PS Ratio n/a Close	5.47
Forward PS Forward PS n/a Close	7.2
PB Ratio PB Ratio n/a Close	3.52
P/FCF Ratio P/FCF Ratio n/a Close	13
PEG Ratio PEG Ratio n/a Close	-0.02

Financial Ratio History

Enterprise Valuation

Protagonist Therapeutics has an Enterprise Value (EV) of 2.29B.

EV / Sales EV / Sales n/a Close	5.27
EV / EBITDA EV / EBITDA n/a Close	9.06
EV / EBIT EV / EBIT n/a Close	12.44
EV / FCF EV / FCF n/a Close	12.53

Financial Position

The company has a current ratio of 12.48, with a Debt / Equity ratio of 0.02.

Current Ratio Current Ratio n/a Close	12.48
Quick Ratio Quick Ratio n/a Close	12.48
Debt / Equity Debt / Equity n/a Close	0.02
Debt / EBITDA Debt / EBITDA n/a Close	0.04
Debt / FCF Debt / FCF n/a Close	0.06
Interest Coverage Interest Coverage n/a Close	0

Financial Efficiency

Return on Equity is 40.75% and Return on Invested Capital is 35.69%.

Return on Equity Return on Equity n/a Close	40.75%
Return on Assets Return on Assets n/a Close	36.95%
Return on Invested Capital Return on Invested Capital n/a Close	35.69%
Revenue Per Employee Revenue Per Employee n/a Close	$3,503,491.94
Profits Per Employee Profits Per Employee n/a Close	$2,219,258.06
Employee Count Employee Count n/a Close	124
Asset Turnover Asset Turnover n/a Close	0.58
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	4.22M
Effective Tax Rate Effective Tax Rate n/a Close	1.51%

Stock Price Statistics

The stock price has increased by 73.24% in the last 52 weeks. The beta is 2.25, so Protagonist Therapeutics's price volatility has been higher than the market average.

Beta Beta n/a Close	2.25
52-Week Price Change 52-Week Price Change n/a Close	73.24%
50-Day Moving Average 50-Day Moving Average n/a Close	48.45
200-Day Moving Average 200-Day Moving Average n/a Close	44.49
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	64.64
Average Volume (20 Days) Average Volume (20 Days) n/a Close	1,022,740

Income Statement

In the last 12 months, Protagonist Therapeutics had revenue of 434.43M and earned 275.19M in profits. Earnings per share was 4.47.

Revenue Revenue n/a Close	434.43M
Gross Profit Gross Profit n/a Close	431.47M
Operating Income Operating Income n/a Close	252.84M
Net Income Net Income n/a Close	275.19M
EBITDA EBITDA n/a Close	252.84M
EBIT EBIT n/a Close	252.84M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	4.47

Full Income Statement

Balance Sheet

The company has 97.25M in cash and 10.87M in debt, giving a net cash position of 86.38M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	97.25M
Total Debt Total Debt n/a Close	10.87M
Net Cash Net Cash n/a Close	86.38M
Retained Earnings Retained Earnings n/a Close	-340.52M
Total Assets Total Assets n/a Close	742.13M
Working Capital Working Capital n/a Close	570.75M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 184.15M and capital expenditures -1.35M, giving a free cash flow of 182.8M.

Operating Cash Flow Operating Cash Flow n/a Close	184.15M
Capital Expenditures Capital Expenditures n/a Close	-1.35M
Free Cash Flow Free Cash Flow n/a Close	182.8M
FCF Per Share FCF Per Share n/a Close	2.97

Full Cash Flow Statement

Margins

Gross margin is 99.32%, with operating and profit margins of 58.2% and 63.34%.

Gross Margin Gross Margin n/a Close	99.32%
Operating Margin Operating Margin n/a Close	58.2%
Pretax Margin Pretax Margin n/a Close	64.32%
Profit Margin Profit Margin n/a Close	63.34%
EBITDA Margin EBITDA Margin n/a Close	58.2%
EBIT Margin EBIT Margin n/a Close	58.2%
FCF Margin FCF Margin n/a Close	42.08%

Dividends & Yields

PTGX does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	11.58%
FCF Yield FCF Yield n/a Close	7.69%

Dividend Details

Analyst Forecast

The average price target for PTGX is $67.5, which is 22.2% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$67.5
Price Target Difference Price Target Difference n/a Close	22.2%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	10

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	33.21
Graham Upside Graham Upside n/a Close	-39.87%

Scores

Altman Z-Score Altman Z-Score n/a Close	33.99
Piotroski F-Score Piotroski F-Score n/a Close	6